# Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma

Source: https://onco.cc/trials/nct03439709/  
OnCo record `nct03439709` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Gamma Knife in Pituitary tumours, run by Samsung Medical Center, with a status the registry has not verified recently.

## Summary

Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma is a phase 3 interventional study registered as NCT03439709 by Samsung Medical Center, with 90 participants planned, started 2018-03-01 and due to reach its primary completion in 2022-06-30. Interventions recorded: Gamma knife radiosurgery, Lanreotide 60Mg Solution for Injection. Conditions recorded: Acromegaly Due to Pituitary Adenoma.

Linked to the technology Gamma Knife because the registry names it ("gamma knife") among its interventions and Pituitary tumours among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03439709
- Phase: 3
- Setting: Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma From an Endocrinological Point of View (MERGE Study): a Randomized, Phase 3 Trial
- Sponsor: Samsung Medical Center
- Enrolled: 90

## Sources

- ClinicalTrials.gov NCT03439709: https://clinicaltrials.gov/study/NCT03439709

## Connected records

- cancers: [Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma](https://onco.cc/cancers/pituitary-tumours/)
- technologies: [Gamma Knife](https://onco.cc/technologies/gamma-knife/)

---
JSON: https://onco.cc/api/v1/entities/nct03439709.json